

Case Docket No. WWELL73.004AUS

Date: April 1, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Buehring et al.

Appl. No.

10/627,884

Filed

July 25, 2003

For

ANTIBODIES FOR

IDENTIFYING AND/OR

ISOLATING AT LEAST ONE CELL POPULATION WHICH IS SELECTED FROM THE GROUP COMPRISING HAEMATOPOIETIC STEM CELLS, NEURONAL STEM

CELLS, NEURONAL PRECURSOR CELLS, MESENCHYMAL STEM CELLS AND MESENCHYMAL

PRECURSOR CELLS

Examiner

Unknown

Group Art Unit:

1645

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

/(Date

Marina L/Gordey, Reg. No. 52,950

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with nine (9) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Case Docket No. WWELL73.004AUS

Date: April 1, 2004

(X) Return prepaid postcard.

Marina L. Gordey Registration No. 52,950 Agent of Record Customer No. 20,995 (805) 547-5580

O:\DOC\$\MXG\MXG-4786.DOC:vr 031804 Docket No.: WWELL73.004AUS

INFORMATION DISCLOSURE STATEMENT

Applicant

Buehring et al.

App. No.

10/627,884

Filed

July 25, 2003

For

PR 0 5 2004

ANTIBODIES FOR IDENTIFYING

AND/OR ISOLATING AT LEAST ONE

CELL POPULATION WHICH IS
SELECTED FROM THE GROUP
COMPRISING HAEMATOPOIETIC
STEM CELLS, NEURONAL STEM
CELLS, NEURONAL PRECURSOR
CELLS, MESENCHYMAL STEM CELLS
AND MESENCHYMAL PRECURSOR

CELLS

Examiner

Unknown

Group Art Unit

1645

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 9 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: <u>April</u> 1, 2804

By:

Marina L. Gordey

Registration No. 52,950

Agent of Record

Customer No. 20,995

(805) 547-5580

	FORM PTO-1449
6	INPORMATIO
A	PR 0 5 2004
CAN TO	(USE SEVER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. WWELL73.004AUS

APPLICATION NO. 10/627,884

ATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Buehring et al.

SEVERAL SHEETS IF NECESSARY)

FILING DATE GROUP
July 25, 2003 GROUP
1645

		U.S.	PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

			F	OREIGN PATENT DOCUMENTS					
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL							YES	NO	
	1	WO 00/06698	2/10/2000	PCT					
	2	WO 01/40466	6/7/2001	PCT					
	3	WO 01/54477	8/2/2001	PCT					
	4	WO 01/75067	10/11/2001	PCT					
	5	WO 02/04508	1/17/2002	PCT			·		
	6	1,074,617	2/7/2001	Europe					
EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	 Conze, Tim et al., "CDCP1 is a novel marker for hematopoietic stem cells," Ann. N.Y. Acad. Sci. (2003), 996:222-226. Scherl-Mostageer M., et al., "Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer," Oncogene, (2001), 20: 4402-4408. 								
							l cancer		
	9 Yin, Amy H., et al. "AC133, a novel marker for human hematopoietic stem and progenitor cells" Blood, (1 5002-5012.					1997) 9			
	├			· · · · · · · · · · · · · · · · · · ·					

O:\DOCS\MXG\MXG-4747.DOC:vr 031104

EXAMINER			
	EY	ΔΝΑΙ	NER